Home > Financial Ratios > NATCO PHARMA

NATCO PHARMA
Core EBITDA Margin

    Back to All Ratios
NATCO PHARMA is part of below Screeners ↓
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results

NATCO PHARMA Last 5 Year Core EBITDA Margin History

[Consolidated]

Mar2023Mar2022Mar2021Mar2020Mar2019
   Core EBITDA Margin(%) 31.6411.8928.9728.3134.79

What is the latest Core EBITDA Margin ratio of NATCO PHARMA ?

The latest Core EBITDA Margin ratio of NATCO PHARMA is 31.64 based on Mar2023 Consolidated results.
Year Core EBITDA Margin
Mar202331.64
Mar202211.89
Mar202128.97
Mar202028.31
Mar201934.79

How is Core EBITDA Margin of NATCO PHARMA Trending?

Years Core EBITDA Margin % Change
Mar2023 31.64
166.11
Mar2022 11.89
-58.96
Mar2021 28.97
2.33
Mar2020 28.31
-18.63
Mar2019 34.79 -

Other Financial Ratios of NATCO PHARMA


Compare Core EBITDA Margin ratio of peers of NATCO PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
NATCO PHARMA ₹18,433.0 Cr 2.1% 2.1% 65.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹351,910.0 Cr -2.9% 0% 59.6% Stock Analytics
CIPLA ₹119,369.0 Cr 5.8% 6.2% 60.9% Stock Analytics
DIVIS LABORATORIES ₹112,930.0 Cr 5% 8% 25.9% Stock Analytics
ZYDUS LIFESCIENCES ₹106,515.0 Cr -2.6% 15.3% 114.4% Stock Analytics
DR REDDYS LABORATORIES ₹98,161.7 Cr 0.9% -1.5% 32.2% Stock Analytics


NATCO PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
NATCO PHARMA

2.1%

2.1%

65.5%

SENSEX

1.9%

2.1%

21.7%


You may also like the below Video Courses